- Product
- It costs ₩867 million to become a physician
- by Kang, Shin-Kook Feb 11, 2020 06:29am
- It is estimated that it costs &8361;867 million from entering medical school to obtaining professional qualification. The Korean Medical Association(KMA)'s research institute for healthcare policy (Director Deok-sun Ahn) announced on the 7th that it has published a research report on the estimation of doctor training costs and public support
- Product
- Lyxumia by Sanofi stops supply in the second half
- by Kim, Min-Gun Feb 10, 2020 06:31am
- Sanofi-Aventis Korea's supply of GLP-1 analog diabetes treatment ‘Lyxumia (Lixisenatide)’ will be discontinued from June this year. According to the distribution industry on the 7th, Sanofi recently announced that it has stopped supplying two formulations, such as 10μg and 20μg of Lyxumia pen, due to company circumstances. Sanofi sa
- Product
- Taltz for interleukin Psoriasis expands Rx Area in hospitals
- by Eo, Yun-Ho Jan 6, 2020 06:22am
- Lilly's interleukin IL-17A antagonist, Taltz, is settling on its prescription area at general hospitals. According to the related industry on the 6th, psoriasis treatment Taltz (Ixekizumab) passed the drug commitee (DC) of Seoul National Hospital recently after Asan Hospital and Severance Hospital among the Big Five. In addition, prescri
- Product
- Samsung completes Phase III of Lucentis Biosimilar
- by Lee, Seok-Jun Jan 2, 2020 06:08am
- Samsung Bioepis’ Lucentis Biosimilar (SB11)' phase III completed. Lucentis' global sales last year were about ￦4.2 trillion. Samsung Bioepis recently announced its last patient visit for the SB11 phase III trial was done. Phase III examined compared non-inferiority with the original Lucentis in a total of 705 patients with Wet Age
- Product
- Oral treatment by Sanofi has the highest number of defects
- by Kim JiEun Dec 26, 2019 06:30am
- Ten defects were found in the same product of the same company a year The Seoul Pharmaceutical Society (Chairman Dong-ju Han), the pharmacy committee (Vice chairman Yong-seok Choi, Head Commissioner Woo-young Chang, Soo-hyun Byun, and Tae-seok Kang), and the Pharmacist Guidance Committee (Chairman Kyung-Jin Jeon and Soo-Yul Lim) announced
- Product
- “Lipitor not sold out”, Pfizer clarifies rumors
- by Kim JiEun Dec 18, 2019 06:24am
- Rumors of cholesterol lowering treatment Lipitor tablet going out of stock have been spreading throughout major pharmacies, but its company clarified the rumor is false. Pfizer Upjohn Korea on Tuesday told Daily Pharm that the manufacturing of Lipitor 10 mg tablet (28BLP/ 90BLT) has no issue at the moment. The company’s statement w
- Product
- Stock-out Cytotec and Livalo V supply to resume from January
- by Kim, Min-Gun Dec 12, 2019 10:52pm
- Some doses of Pfizer Korea’s stomach ulcer preventing drug Cytotec (misoprostol) has run out of stock and the company say the supply would resume around early next year. Sources from the pharmaceutical industry reported on Dec. 11 that there is a temporary shortage on 200 mcg 120 BTL dose of Cytotec. Pin pointing at the delay in manu
- Product
- Metformin impurity amount, theoretically 1/90 of Ranitidine
- by Kim, Jin-Gu Dec 10, 2019 06:31am
- With Metformin, issues of impurity detection have been raised, and it is possible that N-nitrosodimethylamine (NDMA) will be detected much less than earlier Ranitidine or Nizatidine. According to officials at the MFDS on Dec 9, a qualitative structure activity relationship (QSAR) is used as a simple test to determine the toxicity of a su
- Product
- Just over a year since Tamiflu fears after suicide in Busan
- by Jung, Heung-Jun Nov 20, 2019 11:50pm
- Consultation about hallucinations is burden, but can be explained in writing. Tamiflu prescription patients are expected to gradually increase as the flu season approaches this year. Last year, there was a need to consult side effect of hallucinations after the fall of a middle school girl who took Tamiflu in Busan. At the time, The is
- Product
- The Minister Lee, Enhanced post-de-factor management
- by Jung, Heung-Jun Nov 18, 2019 10:21pm
- Lee Eui-kyung, the Minister of MFDS has released a long-term follow-up plan to strengthen the post-de-factor safety management system. On the 15th, the Minister Lee attended Korean Academy of Social & Managed Care Pharmacy and presented the four directions of drug safety management in four categories: patient safety, accessibility, safety
